SSMXF Quote, Financials, Valuation and Earnings

PeptiDream Inc. has a net margin of 11.35% compared to Sysmex Corp.'s net margin of -25.38%. Sysmex Corp.'s return on equity of 9.93% beat PeptiDream Inc.'s return on equity of -10.42%.

Sysmex Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sysmex Corp. has higher upside potential than PeptiDream Inc., analysts believe Sysmex Corp. is more attractive than PeptiDream Inc..

Sysmex Corp. has a beta of 0.936, which suggesting that the stock is 6.434% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.

Sysmex Corp. has a quarterly dividend of $0.13 per share corresponding to a yield of 2.38%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sysmex Corp. pays 37.18% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. Sysmex Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sysmex Corp. quarterly revenues are $859.8M, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. Sysmex Corp.'s net income of $97.6M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, Sysmex Corp.'s price-to-earnings ratio is 18.70x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sysmex Corp. is 1.74x versus 13.13x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma Co., Ltd. has a net margin of 11.35% compared to Sysmex Corp.'s net margin of -24.76%. Sysmex Corp.'s return on equity of 9.93% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.

Sysmex Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sysmex Corp. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe Sysmex Corp. is more attractive than Nxera Pharma Co., Ltd..

Sysmex Corp. has a beta of 0.936, which suggesting that the stock is 6.434% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.

Sysmex Corp. has a quarterly dividend of $0.13 per share corresponding to a yield of 2.38%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sysmex Corp. pays 37.18% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. Sysmex Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sysmex Corp. quarterly revenues are $859.8M, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. Sysmex Corp.'s net income of $97.6M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, Sysmex Corp.'s price-to-earnings ratio is 18.70x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sysmex Corp. is 1.74x versus 2.57x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Stemcell Holdings, Inc. has a net margin of 11.35% compared to Sysmex Corp.'s net margin of --. Sysmex Corp.'s return on equity of 9.93% beat Stemcell Holdings, Inc.'s return on equity of --.

Sysmex Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sysmex Corp. has higher upside potential than Stemcell Holdings, Inc., analysts believe Sysmex Corp. is more attractive than Stemcell Holdings, Inc..

Sysmex Corp. has a beta of 0.936, which suggesting that the stock is 6.434% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sysmex Corp. has a quarterly dividend of $0.13 per share corresponding to a yield of 2.38%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sysmex Corp. pays 37.18% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. Sysmex Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sysmex Corp. quarterly revenues are $859.8M, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. Sysmex Corp.'s net income of $97.6M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, Sysmex Corp.'s price-to-earnings ratio is 18.70x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sysmex Corp. is 1.74x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical Co., Ltd. has a net margin of 11.35% compared to Sysmex Corp.'s net margin of -1.05%. Sysmex Corp.'s return on equity of 9.93% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.

Sysmex Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.76 which suggests that it could grow by 23.73%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than Sysmex Corp., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than Sysmex Corp..

Sysmex Corp. has a beta of 0.936, which suggesting that the stock is 6.434% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.

Sysmex Corp. has a quarterly dividend of $0.13 per share corresponding to a yield of 2.38%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.61% to investors and pays a quarterly dividend of $0.32 per share. Sysmex Corp. pays 37.18% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. Sysmex Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.

Sysmex Corp. quarterly revenues are $859.8M, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. Sysmex Corp.'s net income of $97.6M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, Sysmex Corp.'s price-to-earnings ratio is 18.70x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 181.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sysmex Corp. is 1.74x versus 1.54x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.